Glenmark Sacu V for Heart Failure Treatment in India
Mumbai-based Glenmark Pharmaceuticals has launched its own brand of Sacubitril-valsartan tablets, called Sacu V. The drug is used to treat heart failure and is a Indian generic version of Novartis’ Vymada (sold globally as Entresto).
Heart failure is a chronic condition that affects millions of people worldwide, including a significant number in India. It is a serious medical condition that occurs when the heart cannot pump enough blood to meet the body’s needs.
Recognising the urgent need for more effective treatment options, Glenmark Pharmaceuticals has launched Sacu V, a breakthrough drug specifically designed to address heart failure in India.
The Need for Effective Treatment
Given the high prevalence of heart failure and its impact on patients, there is an urgent need for effective treatment options. Traditional treatments focus on managing symptoms and preventing the condition from worsening but may not address the underlying causes or provide substantial long-term benefits. This creates a significant burden on patients and healthcare systems, highlighting the necessity for innovative therapies.
Glenmark’s Sacu V (Sacubitril-valsartan)
Glenmark Pharmaceuticals, a renowned global pharmaceutical company, has introduced Sacu V as a breakthrough drug for the treatment of heart failure.
Key Features and Benefits of Sacu V
Sacu V (Sacubitril-valsartan) offers several key features and benefits that set it apart from existing treatments. Firstly, it acts as a vasodilator, relaxing blood vessels and improving blood flow, thus reducing the workload on the heart. Additionally, it enhances cardiac contractility, ensuring that the heart can pump blood more effectively.
Glenmark Sacu V (Sacubitril-valsartan) Price in India
The launch of Sacu V is a major development for Glenmark Pharmaceuticals.
Sacu V (Sacubitril-valsartan) generic is priced between Rs 19-35 per tablet, which is significantly lower than the price of Vymada (entresto). This is likely to lead to a significant price erosion in the heart failure drug market in India.
The launch of Sacu V generic is also good news for patients with heart failure. The lower price of the drug will make it more affordable and accessible to more people. This could help to improve the lives of millions of people around the world.
In addition to the lower price, Sacu V is also expected to be more widely available. This means that patients will be able to get Sacu V more easily.
The launch of Sacu V is a positive development for the Indian pharmaceutical industry. It shows that Indian companies are capable of developing and launching high-quality generic drugs at affordable prices.
Availability and Launch in India
Glenmark Pharmaceuticals has launched Sacu V in 50 mg, 100 mg and 200 mg strength.
The medicine is easily available in India. A patient can access this drug once they have doctor prescription.
